<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923869</url>
  </required_header>
  <id_info>
    <org_study_id>SMB Levobupivacaine</org_study_id>
    <nct_id>NCT02923869</nct_id>
  </id_info>
  <brief_title>Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery</brief_title>
  <official_title>Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cleft deformity of the lip and/or palate is one of the commonest major birth defects.&#xD;
&#xD;
      Primary surgery of cleft palates (CP) varies according to the different surgical teams. Its&#xD;
      peculiarity lies in the numerous care management protocols proposed according to the surgical&#xD;
      techniques used, operating time (between M3 and M18 of life), anesthetic technique and&#xD;
      postoperative management.&#xD;
&#xD;
      This surgery must be associated to a specific care management because of potential associated&#xD;
      complications, especially the risk of obstruction of the upper respiratory tract and&#xD;
      respiratory distress majored by the use of morphine anesthetics during and after surgery.&#xD;
&#xD;
      Adequate postoperative analgesia in children is a vital part of perioperative care. Regional&#xD;
      block given preoperatively in combination with general anesthesia (GA) provides good&#xD;
      preemptive analgesia. It is associated with perioperative hemodynamic stability, rapid and&#xD;
      complete recovery and reduced analgesic requirement in the postoperative period.&#xD;
&#xD;
      CP repair is painful, necessitating high doses of intravenous (IV) opioids. Therefore, the&#xD;
      risk of postoperative respiratory depression and airway obstruction is important, and&#xD;
      continuous monitoring is required during the initial 24-h postoperative period. Cleft palate&#xD;
      surgery is not only painful, but may also compromise the airway, particularly in children&#xD;
      with craniofacial syndromes. Opiate analgesia has the potential to further compromise the&#xD;
      airway, whereas bilateral maxillary nerve block can provide analgesia without the risk of&#xD;
      respiratory depression in these vulnerable patients. Bilateral maxillary nerve block is&#xD;
      performed using a suprazygomatic approach and is based on a computer tomography study.&#xD;
&#xD;
      The nerve supply to the hard and soft palate is from the greater and lesser palatine nerves&#xD;
      passing through the sphenopalatine ganglion. The maxillary nerve (MN) provides sensory&#xD;
      innervation of the anterior and posterior palate, the upper dental arch, the maxillary sinus,&#xD;
      and the posterior nasal cavity. Maxillary nerve block (MNB) through the infrazygomatic route,&#xD;
      used for the treatment of trigeminal neuralgia in adults, permits anesthesia of the entire&#xD;
      palatine territory. However, this nerve block has led to complications such as orbital&#xD;
      puncture, intracranial injection, maxillary artery puncture, or posterior pharyngeal wall&#xD;
      injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled double blind study using a computer generated&#xD;
      randomization scheme will be conducted in Assiut University Hospitals and will be carried out&#xD;
      on 60 children undergoing primary cleft palate repair surgery. Combined general anesthesia&#xD;
      and regional bilateral maxillary nerve block (MNB) will be used for anesthesia in these&#xD;
      surgeries.&#xD;
&#xD;
      The study drugs (used in MNB) and randomization will be prepared by the second anesthetist.&#xD;
      The MNB and observed parameters (intraoperative and postoperative) will be done by the first&#xD;
      anesthetist.&#xD;
&#xD;
      Children will be randomly allocated into one of two groups of 30 patients each:&#xD;
&#xD;
      Group L: children will receive 0.15 ml/kg of 0.2% Levobupivacaine&#xD;
&#xD;
      Group B: children will receive 0.15 ml/kg of 0.2% Bupivacaine&#xD;
&#xD;
      Preoperative Assessment&#xD;
&#xD;
      The day prior to surgery, all children participating in this study will undergo&#xD;
      pre-anesthetic checkup (preoperative fitness) including detailed history from the parents,&#xD;
      thorough general, physical and systematic examinations. Weight and height of all children&#xD;
      will be carefully recorded.&#xD;
&#xD;
      Anesthetic Technique&#xD;
&#xD;
      Premedication: All children will be premedicated with intramuscular midazolam 0.05 mg/kg&#xD;
      10-20 minutes before induction of general anesthesia.&#xD;
&#xD;
      Monitoring: Pulse Oxymetry (SaO2), Non-Invasive Mean Arterial Blood Pressure (MABP), ECG, End&#xD;
      Tidal CO2 (EtCO2) and Non-Invasive Temperature probes will be applied to each patient.&#xD;
&#xD;
      After 3 minutes of 100% pre-oxygenation, general anesthesia will be induced by Sevoflurane&#xD;
      inhalation 4-6% MAC via facemask then intravenous line will be secured and intravenous fluids&#xD;
      (NaCl 0.9%) will be started at the calculated volume and rate. Fentanyl 1 µg/kg and Propofol&#xD;
      1.5 mg/kg will be given intravenously then intubation with oral RAE tube of the appropriate&#xD;
      size will be inserted and secured. Assisted ventilation will be adjusted to maintain 30-35&#xD;
      mmHg EtCO2. Anesthesia will be maintained with 100% O2 and Sevoflurane 2-4% MAC. Broad&#xD;
      spectrum antibiotic will be given to each child participated in the study.&#xD;
&#xD;
      Suprazygomatic MNB: Bilateral suprazygomatic MNB will be performed after complete aseptic&#xD;
      preparation of the skin and before surgery in an anesthetized patient. Success of MNB will be&#xD;
      assessed by the lack of sympathetic response to surgical stimulation.&#xD;
&#xD;
      Data Collection&#xD;
&#xD;
      Demographic data: including age, sex, weight and height.&#xD;
&#xD;
      Intraoperative data: heart rate (HR), mean arterial pressure (MAP), ECG, SaO2, EtCO2 and&#xD;
      Sevoflurane MAC % will be measured every 15 minutes after MNB till the end of the surgery.&#xD;
&#xD;
      Postoperative data: HR, MAP, SaO2 and respiratory rate (RR) will be measured at the same&#xD;
      times of pain assessment times.&#xD;
&#xD;
      Pain Severity: pain will be assessed by the second anesthetist blinded to the study drug&#xD;
      used. Pain score will be evaluated on arrival to recovery room (T0), 1, 2, 4, 6, 8, 12 and 24&#xD;
      hours using the FLACC pain scale (Face, Legs, Activity, Cry and Consolability scale). If&#xD;
      FLACC score ≥ 3, IV nalbuphine 0.1 mg/kg will be given for supplemental analgesia.&#xD;
&#xD;
      Time of the first analgesic requirement, total dose of nalbuphine consumption or any adverse&#xD;
      effects (sedation, vomiting, respiratory depression, bleeding at the puncture site or any&#xD;
      systemic toxicity related to the local anesthetic) will also be recorded.&#xD;
&#xD;
      Sedation score: will be evaluated by the 4 points (1-4) score. (Awake and alert -1, Sedated&#xD;
      and responding to verbal command-2, Sedated and responding to mild stimulus-3, Sedated and&#xD;
      responding to moderate to severe physical stimulus-4).&#xD;
&#xD;
      Blood glucose level will be measured before MNB, 15 minutes after block and 2 hours after end&#xD;
      of surgery.&#xD;
&#xD;
      Statistical Analysis&#xD;
&#xD;
      All data will be collected and processed using SPSS (SPSS Inc., Chicago, Illinois, USA)&#xD;
      version 20. All results will be expressed as mean ± SD, range, numbers and percentages.&#xD;
      Categorical data will be compared using Chi-Square test. Non parametric data will be compared&#xD;
      using the Mann-Whitney U test. Numerical data will be compared using the Independent Samples&#xD;
      Student t-Test. P ˂ 0.05 will be considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recovery after surgery</measure>
    <time_frame>2 hours</time_frame>
    <description>sedation of the child in the recovery room will be monitored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FLACC score</measure>
    <time_frame>24 hours</time_frame>
    <description>Nalbuphine will be given when visual analogue score ≥ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and Postoperative Complications</measure>
    <time_frame>24 hours</time_frame>
    <description>percentage of patients with any complications will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Recovery After Cleft Palate Surgery</condition>
  <arm_group>
    <arm_group_label>Group L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children will receive 0.15 ml/kg of 0.2% Levobupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children will receive 0.15 ml/kg of 0.2% Bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.</description>
    <arm_group_label>Group L</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 1-10 years&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
          -  ASA I or II&#xD;
&#xD;
          -  Primary cleft palate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any allergy to local anesthetics&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Local infection or injury at site of MNB&#xD;
&#xD;
          -  Concomitant rhinoplasty&#xD;
&#xD;
          -  Associated other congenital anomalies&#xD;
&#xD;
          -  History of upper or lower airway diseases&#xD;
&#xD;
          -  History of sleep apnea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HAMDY A YOUSSEF, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 30, 2016</study_first_submitted>
  <study_first_submitted_qc>October 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>MOHAMED F. MOSTAFA</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Levobupivacaine</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Nerve Block</keyword>
  <keyword>Cleft Palate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cleft Palate</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

